Highbridge Capital Management LLC acquired a new stake in shares of ContraFect Co. (NASDAQ:CFRX) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 178,861 shares of the biotechnology company’s stock, valued at approximately $859,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in CFRX. HighTower Advisors LLC bought a new stake in ContraFect during the 4th quarter valued at about $61,000. Avantax Planning Partners Inc. bought a new stake in shares of ContraFect in the 1st quarter valued at about $72,000. WealthTrust Axiom LLC bought a new stake in shares of ContraFect in the 1st quarter valued at about $72,000. Rhumbline Advisers raised its holdings in shares of ContraFect by 58.4% in the 4th quarter. Rhumbline Advisers now owns 18,715 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 6,901 shares in the last quarter. Finally, Opal Wealth Advisors LLC bought a new stake in shares of ContraFect in the 1st quarter valued at about $96,000. Institutional investors own 66.03% of the company’s stock.
Several equities research analysts have recently commented on CFRX shares. Chardan Capital boosted their price target on shares of ContraFect from $15.00 to $17.50 and gave the company a “buy” rating in a report on Tuesday, March 16th. Mizuho reaffirmed a “buy” rating and issued a $10.00 price objective (down previously from $12.00) on shares of ContraFect in a research report on Wednesday, March 31st. Finally, WBB Securities assumed coverage on shares of ContraFect in a research report on Wednesday, March 31st. They issued a “speculative buy” rating and a $6.50 price objective on the stock.
ContraFect (NASDAQ:CFRX) last released its earnings results on Monday, May 17th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. On average, sell-side analysts predict that ContraFect Co. will post -1.18 EPS for the current year.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible.
Recommended Story: What is a price target?
Want to see what other hedge funds are holding CFRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ContraFect Co. (NASDAQ:CFRX).
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.